论文部分内容阅读
用ELISACA125检测2163例患者及正常妇女30例，CA125阳性男性13．88％（128／922），女性18．53％（230／1241），两组之间无显著差异（P＞0．50）。卵巢癌患者CA125阳性为53．85％（21／39），肝癌患者CA125阳性为43．75％（21／48），肺癌患者CA125阳性为53．84％（17／31），胸（腹）积液患者CA125阳性为56．76％（21／37），分别与正常对照组相比，均有显著性差异（P＜0．05）。
ELISACA125 was used to detect 2163 patients and 30 normal women. CA125 positive men was 13.88% (128/922) and women were 18.53% (230/1241). There was no significant difference between the two groups (P>0.50). . The CA125 positive rate in ovarian cancer patients was 53.85% (21/39). The CA125 positive rate in liver cancer patients was 43.75% (21/48). The CA125 positive rate in lung cancer patients was 53.84% (17/31). Chest (abdominal) The positive rate of CA125 in effusion patients was 56.76% (21/37), which was significantly different from that in the normal control group (P<0.05).